‘Diseases Don’t Discriminate’: CISCRP Hopes To Improve Trial Diversity With Targeted Messaging

The Center for Information & Study on Clinical Research Participation partnered with drug makers to bring trial awareness to diverse communities and also to help along companies’ own diversity efforts.

• Source: Alamy

It’s easy for consumers to take the availability of drugs for granted when they’re picking up a prescription or getting an injection at the doctor’s office, but the process of making those drugs available through expensive and complex clinical development is hard, Center for Information & Study on Clinical Research Participation (CISCRP) senior director for marketing and outreach Joan Chambers explained in an interview. Increasing awareness of the clinical trial process and need for those trials to enroll a broad spectrum of participants is part of what CISCRP wanted to accomplish with its ongoing awareness campaign.

The CISCRP’s International Clinical Trial Outreach and Awareness Initiative started in November 2019 and consisted of an ad campaign over multiple channels, including social media and email campaigns, targeted digital outreach through online community publications around the country and printed inserts in copies of USA Today in

Citeline Award Nominee

Scrip is interviewing the companies shortlisted for the inaugural champion of diversity and inclusion in clinical research award, to highlight some of the best practices in this urgent area. Watch for additional interviews to come, and follow the Citeline Awards, to be held 7 April 2022, for more information.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diversity & Inclusion

Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India

 

Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Publisher’s Spotlight: The Winners Of The 2024 Citeline Awards

 

Congratulations to the winners of the 2024 Citeline Awards, held 8 May in Boston. 

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

More from ESG

Why Global Pull Incentives Matter For AMR Drugs

 
• By 

The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.

Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

 

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.